洛曼妥珠單抗
洛曼妥珠單抗（INN：rosmantuzumab[1]；開發代號：OMP-131R10）是一種靶向RSPO3的人源化單克隆抗體，設計用於治療癌症。[2][3][4]
| 單克隆抗體 | |
|---|---|
| 種類 | ? |
| 目標 | RSPO3 |
| 臨床資料 | |
| 其他名稱 | OMP-131R10 |
| ATC碼 |
|
| 識別資訊 | |
| CAS號 | 1684393-04-1 |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化學資訊 | |
| 化學式 | C6456H9954N1714O2048S46 |
| 摩爾質量 | 145,825.36 g·mol−1 |
參考資料
- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115 (PDF). WHO Drug Information. 2016, 30 (2) [2024-03-24]. （原始內容存檔 (PDF)於2018-02-05）.
- ^ Katoh M. Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review). Int. J. Mol. Med. August 2018, 42 (2): 713–725. PMC 6034925
. PMID 29786110. doi:10.3892/ijmm.2018.3689.
- ^ Katoh M. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review). Int. J. Oncol. November 2017, 51 (5): 1357–1369. PMC 5642388 . PMID 29048660. doi:10.3892/ijo.2017.4129.
- ^ Katoh M, Katoh M. Molecular genetics and targeted therapy of WNT-related human diseases (Review). Int. J. Mol. Med. September 2017, 40 (3): 587–606. PMC 5547940 . PMID 28731148. doi:10.3892/ijmm.2017.3071.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Rosmantuzumab （頁面存檔備份，存於網際網路檔案館）, American Medical Association.
